Skye Bioscience Inc. (SKYE)
NASDAQ: SKYE
· Real-Time Price · USD
1.45
-0.08 (-5.23%)
At close: Oct 16, 2025, 3:59 PM
1.47
1.38%
After-hours: Oct 16, 2025, 07:51 PM EDT
-5.23% (1D)
| Bid | 1.48 |
| Market Cap | 44.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.37M |
| EPS (ttm) | -1.06 |
| PE Ratio (ttm) | -1.37 |
| Forward PE | -1.25 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.56 |
| Volume | 704,192 |
| Avg. Volume (20D) | 781,254 |
| Open | 1.53 |
| Previous Close | 1.53 |
| Day's Range | 1.45 - 1.57 |
| 52-Week Range | 1.14 - 5.96 |
| Beta | 2.35 |
| Ex-Dividend Date | n/a |
About SKYE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SKYE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-60%
Skye Bioscience shares are trading lower after the...
Unlock content with
Pro Subscription
3 months ago
+32.87%
Skye Bioscience shares are trading higher after the company announced the debut of its "Anatomy of Progress" nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab.
